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6 months. eSWt seems to be a powerful, non-pharmaco-
logical tool that produces rapid pain relief and functional 
improvement and aids the normalization of the vascular 
and metabolic impairments which characterize BMeSH.
Keywords Bone marrow edema syndrome · 
extracorporeal shock wave therapy · Hip · Femoral head · 
conservative treatment · Magnetic resonance imaging
Introduction
the term bone marrow edema (BMe) describes a wide 
range of focal bone lesions of different origin and is most 
likely a vascular reaction to external or internal disorders 
[1]. although the correlations with other diseases such as 
aseptic osteonecrosis, algodistrophy, trabecular microf-
ractures and osteoporosis of pregnancy are still debated, 
bone marrow edema syndrome (BMeS) is now an accepted 
clinical entity. It is typified by an “inflammatory pattern” 
in MRI (low signal intensity in t1-W and high signal 
intensity in t2-W sequences). typical BMe histologi-
cal features are not marked by intra or extracellular fluid 
effusion, but rather depending on the etiology, by fibrosis 
and inflammatory infiltrate which often reflects the occur-
rence of pain in the affected bone segment [2, 3]. BMeS 
usually affects the epiphyses of weight-bearing joints—hip, 
knee, foot and ankle—although it may manifest itself as a 
“migratory” BMe with multiple episodes in different loca-
tions [4, 5].
the hip is the most common site of BMeS. Bone 
marrow edema syndrome of the hip (BMeSH) is a non-
traumatic, disabling, painful condition, which was first 
described in females during the third trimester of pregnancy 
[6], although it is found more commonly in middle-aged 
Abstract there is no gold standard for treatment of bone 
marrow edema syndrome of the hip (BMeSH). Usually, 
treatment is conservative, owing to the favorable and self-
limiting prognosis. In musculoskeletal disorders, the effec-
tiveness of extracorporeal shock wave therapy (eSWt) has 
been widely recognized and recent research supports its use 
in the treatment of the first stages of avascular osteonecro-
sis of the proximal femur and in other conditions where 
bone marrow edema is present. On this basis, we per-
formed a prospective study to evaluate the effectiveness of 
eSWt in normalizing the symptoms and imaging features 
of BMeSH. twenty consecutive symptomatic patients 
underwent two treatments of high-energy eSWt and were 
followed-up at 2, 3 and 6 months, with a final clinical fol-
low-up at mean 15.52 ± 1.91 months. Patients underwent 
magnetic resonance imaging of the hip and were evaluated 
according to the Harris hip score. the mean improvement 
in HHS over the course of the study was of 58.5 ± 14.9 
points (p < 0.0001), and the mean edema area reduced from 
981.9 ± 453.2 mm2 pre-treatment to 107.8 ± 248.1 mm2 at 
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men. It is also referred to as “transient osteoporosis,” “tran-
sitory demineralization” and “migratory osteolysis”—
names which emphasize the transient nature of the radio-
logically apparent bone loss [7]. BMeSH is normally 
spontaneously self-limiting within 4–24 months [4]; how-
ever, there is a risk of fracture due to the weakened bone 
architecture [8]. Progression to avascular osteonecrosis 
(aVn) is a rare occurrence, although it has been described 
in the literature [4, 9–11].
there is no gold standard for the treatment of BMeSH; 
treatment is traditionally conservative and includes reduced 
weight-bearing, physical therapy, analgesics and vasoactive 
prostacyclin analog drugs like iloprost (IP), although some 
authors have even resorted to treating the condition surgi-
cally, performing a bone core decompression [4, 12, 13]. 
However, there is consensus regarding the importance of an 
early treatment to relieve pain and to avoid weakening the 
bone trabeculae which could potentially lead to a collapse 
of the subchondral bone.
extracorporeal shock wave therapy (eSWt) has proved 
to be effective in treating musculoskeletal disorders due to 
its angiogenic, analgesic and anti-inflammatory effects [14–
18]. clinical trials also highlight their effectiveness in treat-
ing the early stages of aVn, reducing the bone edema and 
pain [19–21]. Moreover, recent experimental studies have 
shown the beneficial effect of shock waves (SW) on the 
metabolic processes which regulate bone homeostasis, with 
induction of bone formation in healthy bone and reduc-
tion in bone loss in osteoporosis [22, 23]. On this basis, we 
hypothesized that SW could be effective in the treatment of 
BMeSH, accelerating the resolution of the bone edema and 
thus relieving the pain. the aim of this prospective study 
was to evaluate the effectiveness of eSWt in relieving pain 
and normalizing the MRI appearance of BMeSH.
Materials and methods
From January to June 2012, twenty consecutive patients (12 
male, 8 female), aged from 34 to 55 (mean 43.23 years), 
underwent high-energy shock wave treatment for sympto-
matic BMeSH. all cases were classified according to the 
association Research circulation Osseous (aRcO) stag-
ing system [24]. the inclusion criterion for the study was 
a classification of aRcO stage I on MR images: BMe and 
joint effusion without necrosis. exclusion criteria were 
BMe with any finding of avascular necrosis (demarcation) 
or advanced osteoarthritis (ahlback’s grade 3 or 4 [25]). 
Patients who had received any previous treatment were 
also excluded, along with those who had contraindications 
for eSWt. the average time period between the onset of 
symptoms and the beginning of treatment was 4.2 weeks 
(range 4–7 weeks). Informed consent was obtained from 
each patient, and the study was approved by the scientific 
review board of our institution.
all patients were evaluated by a single examiner accord-
ing to the Harris hip score (HHS), which includes pain, 
ability to walk unaided, autonomy in daily activities and 
range of motion. HHS was assessed before treatment 
(t0), at 2 months (t1), 3 months (t2) and 6 months (t3) 
post-treatment). Prior to the writing of this report (mean 
15.52 ± 1.91 months), a final clinical visit was performed, 
and HHS was again assessed. all the patients also under-
went a hip MRI examination pre-treatment and at the sec-
ond and sixth month post-treatment. an experienced radiol-
ogist calculated the edema area on the resulting films using 
the Sectra PacS software (linköping, Sweden).
the therapeutic protocol consisted of two ses-
sions of shock wave therapy, 48 h apart, using a shock 
wave electromagnetic source [Modulith SlK Storz 
Medical,Switzerland] fitted with a double ecographic and 
radiographic pointing device. each treatment consisted of 
4,000 shots at high-energy level, with mean energy flux 
density (eFD) value of 0.5 mJ/mm2 (range 0.4–0.6 mJ/
mm2). Partial weight-bearing (two crutches) was prescribed 
for 30 days after treatment.
Statistical analysis
the mean and standard deviations (SD) were calculated 
for the HHS values at each of the five time points (t0 
through to t3 and final follow-up). the mean change and 
SD in HHS were calculated between each set of results, 
and the statistical significance calculated using the Stu-
dent’s t test.
Results
the treatment was well tolerated, and none of the patients 
experienced side effects. all patients showed a dramatic 
improvement in HHS at t1 (2 months post-treatment), and 
almost all patients continued to improve over the follow-up 
period (table 1). the mean improvement in HHS over the 
course of the study was of 58.5 ± 14.9 points (range 31.2–
81.5, p < 0.0001). the mean improvements were strongly 
statistically significant between t0 and t1 and between 
t1 andt2 (p < 0.0001) and less significant between t2 and 
t3 (p < 0.01). the mean improvement was not significant 
between 6 months (t3) and final follow-up.
the MRI findings demonstrated the progressive regres-
sion of the BMe (Figs. 1, 2). Pre-treatment, the mean 
edema area of the cohort was 981.9 ± 453.2 mm2. the larg-
est improvement was seen at t1, when the mean edema area 
had more than halved, to 469.5 ± 306.8 mm2. at the final 
MRI examination at t3, the mean edema area had reduced 
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Table 1  Harris hip scores: pre-
treatment (t0), 2 months (t1), 
3 months (t2), 6 months (t3), 
and at final follow-up
* Final follow-up performed 
at mean 15.52 ± 1.9 months. 
HHS rounded to nearest whole 
number
Patient no. HHS at t0 HHS at t1 HHS at t2 HHS at t3 HHS at final 
follow-up*
1 69 93 99 100 100
2 45 92 96 92 94
3 46 97 98 100 100
4 32 86 97 100 100
5 11 77 85 96 92
6 65 86 100 100 100
7 20 69 91 96 92
8 30 85 86 94 93
9 24 73 85 86 100
10 65 95 90 95 90
11 38 76 92 96 98
12 24 62 90 86 90
13 31 82 89 86 88
14 48 83 92 96 100
15 25 77 89 96 93
16 42 95 96 100 100
17 15 60 91 95 92
18 29 72 92 95 92
18 39 82 88 100 100
20 43 82 88 95 97
Mean ± std. dev 39.08 ± 19.66 81.28 ± 10.8 91.76 ± 4.49 95.06 ± 4.53 95.55 ± 4.29
Fig. 1  Pre- and 6 months post-
treatment t1-weighted images 
showing the normalization of a 
large bone marrow edema of the 
left femoral head, in a 47-year- 
old male patient. the circle 
marks the edema
Fig. 2  Pre- and 6 months post-
treatment t2-weighted images 
of the same patient
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to 107.8 ± 248.1 mm2. these reductions were highly statis-
tically significant at both time points (p > 0.0001).
Discussion
there is still debate regarding the pathogenesis and impli-
cations of BMe, and this is reflected in the lack of a gold 
standard in the treatment of this condition. the rationale 
for using eSWt to treat BMe originates from the analysis 
of the recent discoveries about the mechanism of action 
of SW on musculoskeletal tissues, and the clinical results 
reported in other conditions that have similar features to 
BMeSH. SW have already been used in the treatment of 
osteonecrosis of the femoral head and have been shown 
to reduce the extension of the necrotic area and avoid fur-
ther bone collapse. therefore, it is possible that SW may 
significantly delay the need for a total hip replacement. 
Furthermore, SW induce a significant reduction in the 
extent of the BMe and of the associated pain [19–21, 26, 
27]. the main mechanism by which SW act on tissues, 
even if still not completely understood, is probably a neo-
angiogenic effect, mediated by several specific factors 
which include nitroxide (nO). this is a vasoactive mole-
cule produced by endothelial resident cells via endothelial 
nO-synthase (enOS), and it is widely expressed in both 
marrow stromal cells and in cells of bone lineage [17, 28]. 
the link between nO activity and bone homeostasis is 
probably due also to the abundance of endothelial cells of 
the bone marrow stroma. In bone healing, the stimulus on 
new vessel ingrowth improves blood supply and initiates 
tissue regeneration [15]. nO acts also as a powerful inhib-
itor of bone resorption and causes rapid detachment and 
contraction of osteoclasts, while inducing a simultaneous 
activation of the osteoblasts [29, 30]. It also regulates the 
receptor activator of nuclear factor kappa-B ligand ver-
sus osteoprotegerin ratio (RanKl/OPg) promoting the 
differentiation of monoblastic precursors into the osteo-
clastic lineage. experimental studies confirm the role of 
nO derived organic nitrates, including nitroglycerin, in 
limiting the bone loss associated with estrogen deficiency 
[31]. SW also stimulate osteoblasts and periosteal cells 
and induce the osteogenic differentiation of mesenchy-
mal stem cells [32, 33]. Furthermore, SW significantly 
increase the production of osteocalcin, c-terminal procol-
lagen type I (bone matrix deposition marker) and of sev-
eral growth factors [22]. a noticeable increase in vascular 
endothelial growth factor (VegF), transforming growth 
factor (tgF-Beta1), bone morphogenetic protein (BMP-
2), von Willebrand factor (vWF) and alkaline phosphatase 
(alP) was found in peripheral blood of patients treated 
with SW for non-unions and aVn of the femoral head 
[16, 34].
In addition to these stimulating biochemical effects, 
recent research emphasizes the direct role of SW on bone 
modeling and remodeling. In a preliminary in vitro study, 
tamma et al. [22] showed that the acoustic pulse increases 
the proliferation and the differentiation of osteoblasts and 
that it reduces the production of pro-osteoclastogenic fac-
tors. Furthermore, experimental studies showed that bone 
microarchitecture can be affected by SW. Unfocused 
eSWt was effective in inducing bone formation in healthy 
bone, whereas in osteoporotic bone it reduced bone loss, 
indicating that eSWt might be useful for the treatment 
of osteopenia and osteoporosis [23]. In addition, previous 
clinical experience in aVn of the femoral head and of the 
lunate verified a strong correlation between eSWt and the 
regression of marrow edema and of pain [19, 35]. On the 
basis of this scientific evidence, we decided to use eSWt 
for addressing the vascular and metabolic disorders that 
characterize BMeSH, “resetting” the mechanisms that gov-
ern the bone homeostasis.
We observed a quick positive response to the ther-
apy. the most marked clinical improvement occurred at 
2 months post-treatment, where the mean HHS values 
were significantly higher than those recorded pre-treat-
ment (p < 0.001). at this point, all patients had already 
regained a significant level of autonomy in their daily 
lives with a marked reduction in pain, which corresponded 
with the progressive normalization of MRI features. From 
3 to 6 months post-treatment, the improvement in scores 
was more gradual, but still statistically significant with a 
gain of 10.6 points (p < 0.001) at t2 and of 3.35 points 
(p < 0.01) at t3. although the area of edema on MRI had 
not disappeared in all cases, the functional results were 
all good or excellent. In acl ruptures of the knee, it has 
been shown that the edema or bone bruise is not always 
linked to pain [36, 37], and it has been described that MRI 
abnormalities may take up to 16 months before resolution 
[37].
Our results compare favorably with the most effec-
tive forms of treatment that have been developed recently. 
these include vasoactive drugs, biphosfonates, bone core 
decompression and the anabolic agent teraparatide. In a 
study investigating the efficacy of infusions of iloprost for 
treating BMeSH, aigner et al. [13] reported an improve-
ment in HHS from 64.7 points to 97 points 3 months after 
treatment, while Disch et al. [38] observed an increase 
from 56.5 points pre-treatment to 78.2 at 4 weeks and 80.5 
points at 12 weeks. Jager et al. [39] showed an improve-
ment in HHS from 52 to 79 points at mean 33 months. 
With regard to MR imaging, iloprost treatment produced 
the conversion to aRcO 0 in 33 of 42 patients at 6 months 
[39]. In Meizer et al.’s [40] series, in the MR images of 7 of 
the 27 patients, there was either no improvement or indeed 
deterioration.
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the literature regarding the use of bisphosphonates 
mostly relates to their role in the treatment of aVn. Reports 
that demonstrate their success in treating the clinical and 
MRI features of BMeSH concern either single case studies 
or report diverse anatomic sites. nevertheless, some larger 
cohorts have been reported. Varenna et al. [41] reported 
15 patients treated with intravenous pamidronate; clini-
cal symptoms resolved in 2 months and the MRI features 
of BMe normalized after 3 months. In another study, the 
BMe was resolved on MRI at 6 months in the 8 cases stud-
ied [42]. teriparatide, a treatment for osteoporosis, has also 
been shown to resolve BMeSH 1 month after treatment 
[43].
With regard to core decompression, aigner et al. [13] 
reported an improvement in HHS of 53.7 points pre-treat-
ment to 95.1 at 3 months. Hofmann et al. [44] reported that 
at 33 months post-decompression, mean HHS in ten cases 
had improved from 48 to 98, and on MRI at 3 months post-
operative, there was resolution of the BMe in all eight of 
the patients examined. another study reported that on MRI 
at 6 months, the BMeSH features of 20 out of 20 hips had 
normalized, with a mean HHS of 93.7 [12]. elsewhere, 
core decompression was shown to normalize MRI findings 
at 3 months, although only six patients were studied [45].
although the results of the various current conserva-
tive treatments are similar to those observed in our study, 
it is important to note that eSWt is a simple, non-invasive 
treatment that does not require the assumption of pharma-
cological drugs, thus avoiding the reported potential side 
effects [38, 46]. Our treatment protocol required only two 
short treatments as opposed to the often time-consuming 
extended treatments proposed above.
We hypothesize that the early clinical response to 
high-energy dose treatment may be due to the direct, non-
enzymatic production of nO as experimentally observed 
in vitro with high-energy values [17]. the close anatomi-
cal and functional links between vascular elements, mar-
row stromal and active bone cells may explain the positive 
effects of SW on bone metabolism. the production of nO 
induced by the acoustic stimulus would be the keystone of 
this result because of its dose-dependent, multiple action 
on both endothelial and bone cells. It seems to address both 
the vascular and metabolic impairment that distinguishes 
BMe, acting as a sort of “reset mechanism.”
We are aware that a weakness of this study is the lack 
of a control group. However, this was a retrospective study 
that reports our initial experience with the use of eSWt 
for treating BMeSH, and in the absence of a gold standard 
treatment, we wished to test whether our rationale for its 
efficacy was valid. We believe that this experience might 
form the basis for future prospective controlled studies.
to our knowledge, this is the first study to describe the 
use of SW in BMeSH. Our results show that eSWt is 
effective, bringing a swift clinical improvement, followed 
by a progressive normalization of the MRI appearance. 
consequently, it seems possible that it might also prevent 
the, admittedly rare, development to aVn of the femoral 
head. Furthermore, eSWt is a non-invasive technique that 
is well tolerated and with no side effects. nevertheless, fur-
ther controlled studies, with different treatment protocols 
in terms of number of shots, energy level and frequency 
employed, and the number of treatments, are needed to 
establish the optimal regimen.
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